Evidence map›Paper›PMID 35917013›Full record

ArticleAnnals of surgical oncology2022

Molecular Basis of Extramural Vascular Invasion (EMVI) in Colorectal Carcinoma.

Swati Sonal, Vikram Deshpande, David T Ting, James C Cusack, Aparna R Parikh, Azfar Neyaz, Amaya Pankaj, Martin S Taylor, Anne M Dinaux, Lieve G J Leijssen and 8 more

Abstract read
PubMed Publisher
In one paragraph

Article in Annals of surgical oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.8field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

18 authors at 1 institution in 2 countries.

Swati SonalDepartment of General and Gastrointestinal Surgery, Massachusetts General Hospital & Harvard Medical School, Boston, MA, USA.
Vikram DeshpandeDepartment of Pathology, Massachusetts General Hospital & Harvard Medical School, Boston, MA, USA.
David T TingMassachusetts General Hospital Cancer Center & Harvard Medical School, Boston, MA, USA.
James C CusackDepartment of General and Gastrointestinal Surgery, Massachusetts General Hospital & Harvard Medical School, Boston, MA, USA.
Aparna R ParikhMassachusetts General Hospital Cancer Center & Harvard Medical School, Boston, MA, USA.
Azfar NeyazDepartment of Pathology, Massachusetts General Hospital & Harvard Medical School, Boston, MA, USA.
Amaya PankajMassachusetts General Hospital Cancer Center & Harvard Medical School, Boston, MA, USA.
Martin S TaylorDepartment of Pathology, Massachusetts General Hospital & Harvard Medical School, Boston, MA, USA.
Anne M DinauxDepartment of General and Gastrointestinal Surgery, Massachusetts General Hospital & Harvard Medical School, Boston, MA, USA.
Lieve G J LeijssenDepartment of General and Gastrointestinal Surgery, Massachusetts General Hospital & Harvard Medical School, Boston, MA, USA.
Chloe BoudreauDepartment of General and Gastrointestinal Surgery, Massachusetts General Hospital & Harvard Medical School, Boston, MA, USA.
Joseph J LocascioDepartment of Neurology, Massachusetts General Hospital & Harvard Medical School, Boston, MA, USA.
Hiroko KunitakeDepartment of General and Gastrointestinal Surgery, Massachusetts General Hospital & Harvard Medical School, Boston, MA, USA.
Robert N GoldstoneDepartment of General and Gastrointestinal Surgery, Massachusetts General Hospital & Harvard Medical School, Boston, MA, USA.
Liliana G BordeianouDepartment of General and Gastrointestinal Surgery, Massachusetts General Hospital & Harvard Medical School, Boston, MA, USA.
Christy E CauleyDepartment of General and Gastrointestinal Surgery, Massachusetts General Hospital & Harvard Medical School, Boston, MA, USA.
Rocco RicciardiDepartment of General and Gastrointestinal Surgery, Massachusetts General Hospital & Harvard Medical School, Boston, MA, USA.
David L BergerDepartment of General and Gastrointestinal Surgery, Massachusetts General Hospital & Harvard Medical School, Boston, MA, USA. dberger@partners.org.ORCID http://orcid.org/0000-0002-0328-4235
Harvard University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundExtramural vascular invasion (EMVI) is a known poor prognostic factor in colorectal carcinoma; however, its molecular basis has not been defined. This study aimed to assess the expression of molecular markers in EMVI positive colorectal carcinoma to understand their tumor microenvironment.

methodsImmunohistochemistry was performed on tissue microarrays of surgically resected colorectal cancer specimens for immunological markers, and BRAFV600E mutation (and on the tissue blocks for mismatch repair proteins). Automated quantification was used for CD8, LAG3, FOXP3, PU1, and CD163, and manual quantification was used for PDL1, HLA I markers (beta-2 microglobulin, HC10), and HLA II. The Wilcoxon rank-sum test was used to compare EMVI positive and negative tumors. A logistic regression model was fitted to assess the predictive effect of biomarkers on EMVI.

resultsThere were 340 EMVI positive and 678 EMVI negative chemo naïve tumors. PDL1 was barely expressed on tumor cells (median 0) in the entire cohort. We found a significantly lower expression of CD8, LAG3, FOXP3, PU1 cells, PDL1 positive macrophages, and beta-2 microglobulin on tumor cells in the EMVI positive subset (p ≤ 0.001). There was no association of BRAFV600E or deficient mismatch repair proteins (dMMR) with EMVI. PU1 (OR 0.8, 0.7-0.9) and low PDL1 (OR 1.6, 1.1-2.3) independently predicted EMVI on multivariate logistic regression among all biomarkers examined.

conclusionThere is a generalized blunting of immune response in EMVI positive colorectal carcinoma, which may contribute to a worse prognosis. Tumor-associated macrophages seem to play the most significant role in determining EMVI.

Indexed as

Colorectal NeoplasmsRectal NeoplasmsForkhead Transcription FactorsHumansImmunohistochemistryNeoplasm InvasivenessPrognosisTumor MicroenvironmentForkhead Transcription Factors

Identifiers

PMID35917013
OpenAlexW4289519852

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.